MétaCan
Menu
← Back to cohort
Record W7128916623 · doi:10.22037/jpem.v11i1.45135

The Potential Mechanisms of Cannabidiol in the Treatment of Epilepsy: A Systematic Review

2025· article· en· W7128916623 on OpenAlexaff
Zahra Shafiei, Seyedeh Toktam Masoumian Hosseini, Karim Qayumi, Shahriar Hosseinzadeh, Maryam Alizadeh, Mohsen Masoumian Hosseini

Bibliographic record

VenueDOAJ (DOAJ: Directory of Open Access Journals) · 2025
Typearticle
Languageen
FieldMedicine
TopicCannabis and Cannabinoid Research
Canadian institutionsUniversity of British Columbia
Fundersnot available
KeywordsCannabidiolDravet syndromeEndocannabinoid systemTRPV1Adverse effectDrugAnxiolyticFatty acid amide hydrolaseClinical trial

Abstract

fetched live from OpenAlex

Background: Epilepsy is one of the most prevalent neurological disorders, affecting approximately 50 million individuals globally. Cannabidiol (CBD) has demonstrated efficacy in reducing seizure frequency among patients with drug-resistant epilepsy. However, the precise mechanisms of action and their interactions with the endocannabinoid system remain inadequately understood. Method: The study conducted a systematic review of the literature on the effects of CBD on epilepsy. A systematic literature review was conducted to identify preclinical and cohort studies involving both pediatric and adult patients. The search was performed across Medline (via PubMed), Scopus, Embase, Web of Science, and CINAHL, with the search period ending in August 2024. Data extraction and synthesis were performed, including study design, sample size, participants, treatment used, mechanisms, and findings. Result: Several studies have shown that CBD has antipsychotic, antidepressant, and anxiolytic properties due to its inhibition of Fatty Acid Amide Hydrolase (FAAH), 5-Hydroxytryptamine (serotonin) receptor 1A (5-HT1A), and Transient Receptor Potential Vanilloid 1 (TRPV1) receptors. CBD has been studied for its effect on epilepsy-related receptors and channels and is an effective treatment for drug-resistant seizures in patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS). Gamma-Aminobutyric Acid Type A Receptor (GABAAR) dysfunction leads to neurological and psychiatric disorders and different drug effects. CBD and 2-Arachidonoylglycerol (2-AG) are positive allosteric modulators of GABAARs. CBD and Cannabidivarin (CBDV) have been shown to activate and desensitize TRPV1 both in vitro and in vivo, which may explain why CBD is such an effective antiepileptic drug. CBD is rapidly absorbed and reaches maximum plasma concentrations in children and adults 0.5-6 hours after ingestion. The oral bioavailability of CBD is low (6-10%) and increases when administered with a high-fat, high-calorie meal. CBD inhibits Cytochrome P450 (CYP)2C19 and CYP3A4, increasing N-desmethylclobazam (N-CLB) and drowsiness in patients with epileptic encephalopathy. CBD has been used in the treatment of refractory epilepsy in recent years. Conclusion: Epilepsy is a chronic hyperexcitability disorder caused by various defects in the brain's neuronal networks. CBD may be able to treat epilepsy by modulating the endocannabinoid system, thereby counteracting some of the functional effects of CB1 receptor activation in the central nervous system.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.013
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.008
Threshold uncertainty score0.020

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.013
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0060.006
Bibliometrics0.0070.008
Science and technology studies0.0010.001
Scholarly communication0.0020.002
Open science0.0020.001
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0060.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.128
GPT teacher head0.541
Teacher spread0.413 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueDOAJ (DOAJ: Directory of Open Access Journals)→Same topicCannabis and Cannabinoid Research→French-language works237,207→